BIO vs JPM Stock Comparison

BIO currently leads JPM in this stock comparison, with AIQ scores of 73 vs 64. The clearest difference is value, while JPM has the stronger quality profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 9 points
BIO
Healthcare
vs
JPM
Financial Services
BIO
Bio-Rad Laboratories, Inc.
Leads
Price
$370
Day move
+3.34%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare
JPM
JPMorgan Chase & Co.
Price
$324
Day move
-1.77%
AIQ Score
64/100
Best edge
Quality
Sector
Financial Services

What is the main difference between BIO and JPM?

BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Bio-Rad Laboratories, Inc. vs JPMorgan Chase & Co.

Data as of Nov 18, 2026· market close· Cross-sector · Healthcare vs Financial Services· Coverage 62/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 6/10

BIO leads

BIO leads by 9 AIQ points, primarily on Value and Momentum.

Competitive: 3 of 5 evidence groups support BIO, and its current signal state is conflicted.

Evidence agreement: 3 of 5Comparison trend: Stable
BIO

Bio-Rad Laboratories, Inc.

Leads
AIQ Score
73/100
AIQ Edge Score
10/10
JPM

JPMorgan Chase & Co.

AIQ Score
64/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors BIO over JPM, 73 versus 64 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value and momentum, while JPM holds the stronger quality profile. BIO also shows the stronger technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor BIO today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. BIO lead: Stable — the AIQ differential has held near 9 points over 30 sessions.

Compare Bio-Rad Laboratories, Inc. and JPMorgan Chase & Co. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BIO
-51.1%
JPM
+123.4%

Total return comparison

Growth of $10,000, distributions reinvested

BIO $4,886 · JPM $22,337

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BIO and JPM against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BIO advantage
0
JPM advantage
  • Value80 vs 10
    BIO +70
  • Quality61 vs 86
    JPM +25
  • Risk Resilience74 vs 87
    JPM +13
  • Momentum79 vs 67
    BIO +12

3 of 5 evidence groups favor BIO. BIO’s edge is concentrated in value and momentum; JPM keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

BIO0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
JPM0 AIQ

No factor moved materially.

New signals

  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon

BIO's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — BIO and JPM both carry a full feed there.

The central trade-off

BIO (Bio-Rad Laboratories, Inc.): the stronger current systematic profile, led by value and momentum.

JPM (JPMorgan Chase & Co.): the counter-case, on quality, risk resilience.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BIO

BIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BIO

BIO on combined revenue and EPS growth.

Value

BIO

BIO on the peer-relative Value factor, by 70 points.

Momentum

BIO

BIO on the Momentum factor, by 12 points.

Lower downside

JPM

JPM on Risk Resilience, by 13 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBIOJPMNote
Implied upside to target—+15.1%Level
Target dispersion—+30.3%Lower is tighter analyst agreement
ConsensusHoldBuyContext, not a primary driver
Analysts covering326Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 5 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBIO73 vs 64
FundamentalsEvenEPS growth 23.3% vs -27.6%; TTM ROE 6% vs 4.1%; gross margin 51.3% vs 63.2%; operating margin 4.6% vs 28.2%
ValuationBIOValue 80 vs 10
TechnicalsBIOPrice vs 50-day -0.7% vs -4.8%; vs 200-day 15.6% vs 6.6%
Risk ResilienceJPMRisk Resilience 74 vs 87
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BIO and JPM and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is moderate at 9 points.
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

BIO lead: Stable — the AIQ differential has held near 9 points over 30 sessions.

Jun 1BIO leads above the line · JPM leads belowNov 18
Today
BIO +9
73 vs 64
7 sessions ago
BIO +10
75 vs 65
30 sessions ago
BIO +9
72 vs 63
90 sessions ago
BIO +10
73 vs 63

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only BIO

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.56%)
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
JPMConflicted

6 bullish / 1 bearish / 1 neutral, conflicted

Only JPM

  • Bollinger Band Squeeze — neutral, volatility, short horizon (5.9%)
  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
  • Low Volume Rally Warning — bearish, volume, short horizon (0.65x)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, TRIX Bullish Signal.

BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).

JPMNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.77%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1JPM closes the Value gap — currently 70 points behind, the largest single contributor to BIO's edge.
  2. 2JPM's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
  3. 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricBIOJPM
Revenue growth (YoY)0.8%-7.6%
EPS growth (YoY)23.3%-27.6%
Gross margin51.3%63.2%
Operating margin4.6%28.2%
Return on equity (TTM)6%4.1%
Debt to equity0.183.32

Performance

BIO leads 5 of 6 windows
MetricBIOJPM
1 week (5 sessions)-4%3.5%
1 month (20 sessions)3.6%1.9%
3 months (63 sessions)3.1%-4.1%
6 months (126 sessions)48%16.2%
Year to date20.9%7.4%
1 year (252 sessions)11.9%8%

Technicals

BIO has the stronger structure
MetricBIOJPM
RSI (14)45.456.1
ADX (14)12.918
Price vs 50-day-0.7%-4.8%
Price vs 200-day15.6%6.6%
Volatility (1M, annualized)31.4%27.4%

Risk

JPM is the more resilient
MetricBIOJPM
Beta0.730.78
Sharpe ratio0.470.44
Sortino ratio0.690.61
Max drawdown-27.2%-15.5%
Current drawdown-6.1%-5.2%
Annualized volatility36.2%22.7%
Value at risk (95%)-3%-2.4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BIO or JPM?

On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against JPM's 64. The edge comes from value and momentum. JPM is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BIO or JPM the better buy right now?

BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor BIO over JPM?

The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 70 points; JPM leads Quality by 25 points; JPM leads Risk Resilience by 13 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BIO or JPM?

Analyst price targets imply not covered upside for BIO and +15.1% for JPM. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BIO or JPM?

BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 70 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BIO or JPM?

BIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BIO or JPM?

BIO on the Momentum factor, by 12 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BIO or JPM?

JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 13 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BIO more profitable than JPM?

The profitability evidence is mixed: gross margin 51.3% vs 63.2%; operating margin 4.6% vs 28.2%; ttm roe 6% vs 4.1%. BIO leads on one measure and JPM on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is BIO's lead over JPM getting stronger or weaker?

BIO lead: Stable — the AIQ differential has held near 9 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the BIO vs JPM verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: JPM closes the Value gap — currently 70 points behind, the largest single contributor to BIO's edge; JPM's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BIO and JPM?

BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. JPM: 6 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BIO is Golden Cross Active (bullish, long horizon). On JPM it is Golden Cross Active (bullish, long horizon).

Compare BIO and JPM with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.